Literature DB >> 28620849

Clinical Management of Dystonia in Childhood.

Quyen N Luc1, Jyes Querubin2.   

Abstract

Dystonia is one of the most frequent movement disorders in childhood. It can impede normal motor development and cause significant motor disability. The diagnostic evaluation of childhood dystonia is challenging due to the phenotypic variability and heterogeneous etiologies. Evidence to guide the diagnostic evaluation and treatment is limited. Assessment is primarily directed by clinical history and distinctive examination findings. Neuroimaging is typically necessary to evaluate for acquired or complex inherited dystonias. A trial of levodopa can be both diagnostic and therapeutic in children with dopa-responsive dystonia. However, for the majority of children with early-onset dystonia, treatment is symptomatic with varying efficacy. There is a paucity of therapeutic trials for childhood dystonia and most treatment recommendations are consensus or expert opinion driven. This review summarizes the available evidence and guidelines on the diagnostic evaluation and pharmacological treatment of childhood-onset dystonia and provides practical frameworks to approach both issues based on best evidence.

Entities:  

Mesh:

Year:  2017        PMID: 28620849     DOI: 10.1007/s40272-017-0243-3

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.930


  119 in total

1.  Atypical phenotypes and clinical variability in a large Italian family with DYT1-primary torsion dystonia.

Authors:  Mattia Gambarin; Enza Maria Valente; Paolo Liberini; Giuseppe Barrano; Alberto Bonizzato; Alessandro Padovani; Giuseppe Moretto; Mirta Fiorio; Bruno Dallapiccola; Nicola Smania; Antonio Fiaschi; Michele Tinazzi
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

2.  Frequency of adverse reactions to prochlorperazine in the ED.

Authors:  J C Olsen; J A Keng; J A Clark
Journal:  Am J Emerg Med       Date:  2000-09       Impact factor: 2.469

3.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

4.  Acute dystonic reactions in childhood to drugs.

Authors:  J L Ayers; K P Dawson
Journal:  N Z Med J       Date:  1980-12-24

5.  Long-term botulinum toxin efficacy, safety, and immunogenicity.

Authors:  Nicte I Mejia; Kevin Dat Vuong; Joseph Jankovic
Journal:  Mov Disord       Date:  2005-05       Impact factor: 10.338

6.  Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  D M Simpson; A Blitzer; A Brashear; C Comella; R Dubinsky; M Hallett; J Jankovic; B Karp; C L Ludlow; J M Miyasaki; M Naumann; Y So
Journal:  Neurology       Date:  2008-05-06       Impact factor: 9.910

Review 7.  Special concerns in defining, studying, and treating dystonia in children.

Authors:  Jonathan W Mink
Journal:  Mov Disord       Date:  2013-06-15       Impact factor: 10.338

8.  Prospective open-label clinical trial of trihexyphenidyl in children with secondary dystonia due to cerebral palsy.

Authors:  Terence D Sanger; Amy Bastian; Jan Brunstrom; Diane Damiano; Mauricio Delgado; Leon Dure; Deborah Gaebler-Spira; Alec Hoon; Jonathan W Mink; Sara Sherman-Levine; Leah J Welty
Journal:  J Child Neurol       Date:  2007-05       Impact factor: 1.987

9.  Dyskinetic cerebral palsy in Europe: trends in prevalence and severity.

Authors:  K Himmelmann; V McManus; G Hagberg; P Uvebrant; I Krägeloh-Mann; C Cans
Journal:  Arch Dis Child       Date:  2009-05-12       Impact factor: 3.791

10.  Is this dystonia?

Authors:  Alberto Albanese; Stefania Lalli
Journal:  Mov Disord       Date:  2009-09-15       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.